Contributions
Abstract: EP847
Type: E-Poster Presentation
Session title: Iron metabolism, deficiency and overload
Background
Many patients with hematologic diseases are heavily transfused and have elevated levels of serum ferritin. Pre-transplant Hyperferritinemia has proved its association with adverse outcomes in hematopoietic stem cell transplant (HSCT) for various diseases, but data on haploidentical HSCT (haplo-HSCT) and severe aplastic anemia (SAA) is absent.
Aims
To determine the impact of hyperferritinemia on outcomes in haplo-HSCT for SAA patients.
Methods
We retrospectively analyzed outcomes of 250 SAA patients who received haplo-HSCT between 2010 and 2018, stratified by pre-transplant status of hyperferritinemia.
Results
The cumulative incidences of neutrophil engraftment at 28 days (95.16 ± 0.25% vs 90.63 ± 0.69%, p = 0.950) and platelet engraftment at 100 days (88.17 ± 0.45% vs 89.06 ± 0.47%, p = 0.105) in the two groups were similar. Hyperferritinemia independently increased the risk of grade II-IV acute graft versus host disease (aGvHD) (HR = 2.065, 95% CI 1.139-3.741, p = 0.017), while it had no impact on grade III-IV aGvHD and chronic GvHD. The risk of transplant-related mortality (TRM) at 100 days (6.45 ± 1.80% versus 9.38 ± 3.64%, p=0.413) and 1 year post-transplant (11.44 ± 2.35 % versus 10.96 ± 3.91%, p = 0.973) were not increased in patients with hyperferritinemia. The 3-year overall survival (85.23 ± 2.81% versus 89.04 ±3.91%, p = 0.648) and failure-free survival (83.32% ± 2.91% versus 82.75 ± 4.73%, p = 0.725) were also comparable between patients with and without hyperferritinemia.
Conclusion
Pre-transplant hyperferritinemia cannot predict transplant outcomes in haplo-HSCT for SAA, and transplant should not be postponed due to high levels of SF in SAA patients. The results should be confirmed in further studies.
Keyword(s): Ferritin, Haploidentical stem cell transplantation, Iron overload, Severe aplastic anemia
Abstract: EP847
Type: E-Poster Presentation
Session title: Iron metabolism, deficiency and overload
Background
Many patients with hematologic diseases are heavily transfused and have elevated levels of serum ferritin. Pre-transplant Hyperferritinemia has proved its association with adverse outcomes in hematopoietic stem cell transplant (HSCT) for various diseases, but data on haploidentical HSCT (haplo-HSCT) and severe aplastic anemia (SAA) is absent.
Aims
To determine the impact of hyperferritinemia on outcomes in haplo-HSCT for SAA patients.
Methods
We retrospectively analyzed outcomes of 250 SAA patients who received haplo-HSCT between 2010 and 2018, stratified by pre-transplant status of hyperferritinemia.
Results
The cumulative incidences of neutrophil engraftment at 28 days (95.16 ± 0.25% vs 90.63 ± 0.69%, p = 0.950) and platelet engraftment at 100 days (88.17 ± 0.45% vs 89.06 ± 0.47%, p = 0.105) in the two groups were similar. Hyperferritinemia independently increased the risk of grade II-IV acute graft versus host disease (aGvHD) (HR = 2.065, 95% CI 1.139-3.741, p = 0.017), while it had no impact on grade III-IV aGvHD and chronic GvHD. The risk of transplant-related mortality (TRM) at 100 days (6.45 ± 1.80% versus 9.38 ± 3.64%, p=0.413) and 1 year post-transplant (11.44 ± 2.35 % versus 10.96 ± 3.91%, p = 0.973) were not increased in patients with hyperferritinemia. The 3-year overall survival (85.23 ± 2.81% versus 89.04 ±3.91%, p = 0.648) and failure-free survival (83.32% ± 2.91% versus 82.75 ± 4.73%, p = 0.725) were also comparable between patients with and without hyperferritinemia.
Conclusion
Pre-transplant hyperferritinemia cannot predict transplant outcomes in haplo-HSCT for SAA, and transplant should not be postponed due to high levels of SF in SAA patients. The results should be confirmed in further studies.
Keyword(s): Ferritin, Haploidentical stem cell transplantation, Iron overload, Severe aplastic anemia